Healthcare / Medical Care FacilitiesThailand
$1.72
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-704.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
N/A
•EV/EBITDA
23.2x
↑ROE
-4.7%
↓Gross Margin
19.1%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.2%
FCF CAGR
—
FCF margin
-12.1%
FCF / Net income
1.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.06B · net income $-406.0M · FCF $-735.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.06B | $6.06B | $5.70B | $5.08B | $6.68B |
| Net Income | $-406.0M | $-406.0M | $351.4M | $-690.3M | $240.0M |
| EBITDA | $448.2M | $448.2M | $382.7M | $161.3M | $1.22B |
| EPS | -0.10 | -0.10 | 0.10 | -0.18 | 0.06 |
| Gross Margin | 19.1% | 19.1% | 20.0% | 17.3% | 29.4% |
| Operating Margin | -4.4% | -4.4% | -4.9% | -11.2% | 6.9% |
| Net Margin | -6.7% | -6.7% | 6.2% | -13.6% | 3.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.40 | 0.77 | 0.61 |
| Current Ratio | 0.41 | 0.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-735.0M | $-735.0M | $-704.5M | $-354.5M | $134.8M |
| Returns | |||||
| ROE | -4.7% | -4.7% | 3.8% | -7.9% | 2.5% |
| Valuation | |||||
| P/E | — | — | 47.15 | — | 92.30 |
| EV/EBITDA | 23.19 | 23.19 | 53.48 | 144.68 | 22.53 |
| P/B | 0.75 | 0.75 | 1.87 | 1.94 | 2.33 |
| Growth & Yield | |||||
| Revenue Growth | 6.3% | 6.3% | 12.2% | -24.0% | — |
| EPS Growth | -205.3% | -205.3% | 153.1% | -384.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.10 → -0.10
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.